Living with Diabetes During COVID-19 – Canadian T2D Survey Insights... Read More

Type 2 diabetes landscape during COVID-19... Read More

Health Canada approves RYBELSUS® (semaglutidetablets) the first and only GLP-1... Read More

Global News

Press releases from the Denmark headquarters.

Media

Visit the pressroom of the website for our headquarters in Denmark where you can access the latest corporate stock exchange announcements, an image library, interim and annual reports and other relevant communication from Novo Nordisk A/S.

For all media inquiries, please contact Corporate Communications:    

Tel: 905-629-6612

Email: KXYH@novonordisk.com

If you have concerns regarding any Novo Nordisk product, please call customer care at 1-800-465-4334 or email nnci-drugsafety@novonordisk.com. In the event of a medical emergency, contact your healthcare professional.